Vistagen Therapeutics Inc.
VTGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.46M
Close$
$0.71
187.4% upside
Current Fair Value
187.4% upsideUndervalued by 187.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.46 Million |
|---|---|
| Enterprise Value | $-19,579,636.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.83 |
| Beta | 0.4 |
| Outstanding Shares | 38,073,926 |
Return
| Return on Equity | -196.19% |
|---|---|
| Return on Assets | -143.49% |
| Return on Invested Capital | -200.16% |
Valuation & Multiples
| P/E Ratio | -0.14 |
|---|---|
| PEG | -0.71 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -15.43 |
| Enterprise Value to EBIT | 0.27 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.14 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 1, 2026
EPS Estimate
$-0.34
Average shareholder expectationRevenue Estimate
$401,400
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
$500,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0691▼ 64.55% |
|---|---|
| Total Calls | 516,800▼ 50.08% |
| Total Puts | 35,700▼ 95.17% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 34.88%▲ 2.32% |
|---|---|
| Total Invested | $8.12M▼ 8.05% |
| Investors Holding | 61▼ 3.00% |
ESG Score
No data
About VistaGen Therapeutics Inc
21 employeesVistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CN...